PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PLRX on Nasdaq
Shares outstanding
61,399,727
Price per share
$1.22
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
46,413,510
Total reported value
$57,202,773
% of total 13F portfolios
0%
Share change
-5,594,174
Value change
-$7,124,088
Number of holders
92
Price from insider filings
$1.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.6% $9,198,699 5,859,044 TANG CAPITAL MANAGEMENT, LLC 03 Mar 2025
CITADEL ADVISORS LLC 5% +2% $3,711,402 +$5,414 3,042,133 +0.15% Kenneth Griffin 02 Feb 2026
VANGUARD GROUP INC 4.9% $3,482,724 3,002,348 The Vanguard Group 30 Jun 2025
Redmile Group, LLC 4.8% $4,545,900 2,895,478 Redmile Group, LLC 31 Dec 2024
BlackRock, Inc. 3.4% $2,440,674 2,104,574 BlackRock, Inc. 30 Jun 2025
Woodline Partners LP 3.3% -57% $2,471,953 -$3,023,924 2,026,191 -55% Woodline Partners LP 31 Dec 2025
MORGAN STANLEY 0.9% -87% $861,460 -$5,043,529 545,228 -85% Morgan Stanley 31 Dec 2025
FMR LLC 0.2% $207,230 131,993 FMR LLC 28 Feb 2025
PRICE T ROWE ASSOCIATES INC /MD/ 0.1% $137,648 87,674 T. Rowe Price Associates, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 0.1% -94% $56,775 -$4,926,946 46,537 -99% Point72 Asset Management, L.P. 31 Dec 2025

As of 31 Dec 2025, 92 institutional investors reported holding 46,413,510 shares of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX). This represents 76% of the company’s total 61,399,727 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TANG CAPITAL MANAGEMENT LLC 10% 6,143,132 +2.3% 0.37% $7,494,621
Blue Owl Capital Holdings LP 4.8% 2,969,199 0% 1.1% $3,622,423
VANGUARD GROUP INC 4.6% 2,818,241 +1.5% 0% $3,438,255
CITADEL ADVISORS LLC 4.2% 2,583,332 +10% 0% $3,151,665
ACADIAN ASSET MANAGEMENT LLC 3.9% 2,364,669 -0.21% 0% $2,879,000
Woodline Partners LP 3.3% 2,026,191 -55% 0.01% $2,471,953
Monaco Asset Management SAM 3.2% 1,938,747 +136% 0.7% $2,365,271
Redmile Group, LLC 2.6% 1,616,228 +1.5% 0.15% $1,971,798
Prosight Management, LP 2.5% 1,555,744 +7494% 0.39% $1,898,008
BML Capital Management, LLC 2.5% 1,546,137 0% 1.7% $1,886,287
TWO SIGMA ADVISERS, LP 2% 1,245,600 +16% 0% $1,519,632
JPMORGAN CHASE & CO 2% 1,212,875 -43% 0% $1,479,707
MARSHALL WACE, LLP 1.8% 1,080,128 +261% 0% $1,317,756
BlackRock, Inc. 1.7% 1,073,272 -24% 0% $1,309,392
UBS Group AG 1.7% 1,062,615 -20% 0% $1,296,390
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,045,818 +3.4% 0% $1,275,898
Centiva Capital, LP 1.6% 1,000,000 0.07% $1,220,000
TWO SIGMA INVESTMENTS, LP 1.6% 953,293 +22% 0% $1,163,017
Peapod Lane Capital LLC 1.4% 886,374 -19% 0.92% $1,081,376
Eversept Partners, LP 1.4% 842,023 +2.1% 0.06% $1,027,268
BANK OF AMERICA CORP /DE/ 1.2% 711,777 +0.53% 0% $868,368
JANE STREET GROUP, LLC 1.1% 653,774 +72% 0% $797,605
GSA CAPITAL PARTNERS LLP 1% 623,698 +288% 0.07% $761,000
GEODE CAPITAL MANAGEMENT, LLC 0.97% 592,696 +0.9% 0% $723,448
JACOBS LEVY EQUITY MANAGEMENT, INC 0.91% 556,938 +52% 0% $679,464

Institutional Holders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 46,413,510 $57,202,773 -$7,124,088 $1.22 92
2025 Q3 50,406,732 $74,592,710 +$1,536,230 $1.48 97
2025 Q2 51,491,424 $59,725,484 -$8,565,167 $1.16 112
2025 Q1 57,869,854 $78,126,006 -$216,549,992 $1.35 138
2024 Q4 64,754,179 $852,599,671 +$21,507,892 $13.17 158
2024 Q3 63,483,171 $714,277,363 -$5,607,911 $11.21 149
2024 Q2 63,896,951 $686,885,070 -$18,557,994 $10.75 141
2024 Q1 65,187,064 $971,256,923 +$41,504,855 $14.90 133
2023 Q4 62,712,668 $1,135,768,923 +$100,850,737 $18.11 133
2023 Q3 60,161,028 $1,043,150,835 +$29,447,949 $17.34 134
2023 Q2 58,042,121 $1,051,734,729 +$9,423,269 $18.12 141
2023 Q1 56,237,135 $1,495,380,265 +$312,862,520 $26.60 143
2022 Q4 44,702,851 $864,087,630 -$14,811,927 $19.33 123
2022 Q3 45,386,319 $948,113,021 +$327,405,105 $20.89 107
2022 Q2 30,133,558 $241,439,678 -$11,245,591 $8.01 81
2022 Q1 31,426,255 $220,339,413 +$4,111,275 $7.01 85
2021 Q4 30,850,148 $416,473,043 +$5,468,177 $13.50 81
2021 Q3 30,380,086 $512,798,759 -$14,863,235 $16.88 75
2021 Q2 30,676,131 $893,270,740 -$1,364,693 $29.12 80
2021 Q1 30,719,770 $1,208,139,215 +$88,069,181 $39.33 76
2020 Q4 28,511,470 $647,801,804 +$7,265,154 $22.72 57
2020 Q3 28,195,401 $635,735,229 +$17,040,139 $22.65 53
2020 Q2 26,908,341 $868,442,000 +$868,442,000 $32.46 36